Quick Links

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps for Cancer Summaries and Commentaries™: Update From San Diego: Advances in Myeloproliferative Neoplasms focuses on trials likely to be of interest to practicing hematologists, immediately or in the near future. Each Recap provides a brief overview of trial data, along with a summary of expert perspectives.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc. and Incyte.

Cancer Summaries and Commentaries™: Update from San Diego—Advances in the Treatment of Myeloproliferative Neoplasms

Release Date: December 29, 2016
Expiration Date: December 29, 2017
Media: Internet - based

Activity Overview

This online activity is designed to update physicians on data that were recently presented in San Diego so they can assess and apply findings to their clinical practices in managing patients with myeloproliferative neoplasms (MPNs). Coverage includes phase III trial data on treatment of myelofibrosis and polycythemia vera, as well as promising results from studies of emerging management strategies for myelofibrosis, polycythemia vera, and systemic mastocytosis.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc. and Incyte.

CME Activity Table of Contents


  • Safety and Efficacy Data From the PERSIST-2 Study
  • Pooled 5-Year Overall Survival Data From COMFORT-I and COMFORT-II
  • 6-Year Follow-up Data From Phase I/II Studies of Momelotinib
  • Efficacy and Safety Data From Phase II Study of Sotatercept

Polycythemia Vera

  • Final Results From the Randomized Phase III PROUD-PV Study
  • Interim Data From the Myeloproliferative Disorders Research Consortium 112 Global Phase III Trial of Frontline Pegylated Interferon Alpha-2a vs Hydroxyurea

Systemic Mastocytosis

  • Preliminary Safety and Activity of a KIT D816V Inhibitor

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, "educational content/audio files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists/hematologists and fellows who treat patients with myeloproliferative neoplasms. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of myeloproliferative neoplasms may also participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Explain clinical study design and major efficacy and safety endpoints of completed/ongoing trials being conducted in patients with MPNs
  2. Discuss recent clinical trial findings concerning novel compounds and strategies for patients with MPNs
  3. Discuss recent clinical trial evidence in the context of evolving treatment paradigms in the management of patients with MPNs

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Faculty, Staff, and Planners' Disclosures


Srdan Verstovsek, MD, PhD
Professor of Medicine
Chief, Section for Myeloproliferative Neoplasms
MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/Research Support: Incyte Corporation, Roche, AstraZeneca, Lilly Oncology, Geron, NS Pharma, Bristol-Myers Squibb, Celgene, Gilead, Seattle Genetics, Promedior, CTI BioPharma Corp, Galena BioPharma, Pfizer, Genentech.

Ruben A. Mesa, MD, FACP
Consultant Hematologist-Mayo Clinic in Arizona
Chair, Division of Hematology and Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Chair, Arizona Cancer Coalition
Professor of Medicine
Mayo Clinic Cancer Center
Phoenix, AZ
Disclosure: Grant/Research Support: Incyte, Gilead, CTI, Promedior. Consultant: Novartis.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®, or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By